{
  "id": 151533,
  "name": "ELI LILLY & COMPANY",
  "slug": "eli-lilly-company",
  "state": "DC",
  "description": "Pharmaceutical/ Health Products",
  "totalSpending": 1500000,
  "filings": 30,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 150000
    },
    {
      "year": 2019,
      "income": 200000
    },
    {
      "year": 2020,
      "income": 200000
    },
    {
      "year": 2021,
      "income": 200000
    },
    {
      "year": 2022,
      "income": 200000
    },
    {
      "year": 2023,
      "income": 200000
    },
    {
      "year": 2024,
      "income": 150000
    },
    {
      "year": 2025,
      "income": 200000
    }
  ],
  "firms": [
    "WILLIAMS AND JENSEN, PLLC"
  ],
  "lobbyists": [
    "SUSAN HIRSCHMANN",
    "MATTHEW HOEKSTRA",
    "ERIN MULLEN",
    "KARINA LYNCH",
    "GEORGE OLSEN",
    "CHERYL JAEGER",
    "ANDREW JONES",
    "CHRISTOPHER HATCHER",
    "NICHOLAS KARELLAS",
    "CHRISTOPHER WILCOX",
    "MELINDA MAXFIELD",
    "GRANT BARBOSA",
    "DANIEL ZIEGLER",
    "JEANNE HAGGERTY",
    "ALEC ARAMANDA",
    "KURT SCHRADER",
    "ROBERT BUTORA"
  ],
  "issues": [
    "MMM",
    "HCR",
    "BUD",
    "TAX",
    "DEF",
    "TRD",
    "CPT",
    "LAW",
    null,
    "PHA"
  ],
  "sampleDescriptions": [
    "Medicare Part D.  CMMI Medicare Part B Demonstration, education about policies impacting reimbursement.",
    "General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and counterfeiting; FDA user fees;  H.R. 1628, American Health Care Act of 2017.",
    "Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act.  H.R. 1892, the Bipartisan Budget Act of 2018.",
    "International and domestic tax issues.  Implementation of H.R. 1, Tax Cuts and Jobs Act.",
    "General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and counterfeiting; FDA user fees.",
    "International and domestic tax issues.  Implementation of H.R. 1, Tax Cuts and Jobs Act, (P.L. 115-97).",
    "Medicare Part D.  CMMI Medicare Part B Demonstration, education about policies impacting reimbursement.  H.R. 6, Support for Policies and Communities Act.",
    "Policies impacting Medicare Part D.",
    "Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).",
    "General education about policies impacting pharmaceutical development, approval and reimbursement.",
    "International and domestic tax issues.  Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).",
    "Policies impacting Medicare Part D and Part B reimbursement policies.",
    "General education about policies impacting pharmaceutical development, approval and reimbursement.  \nS. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.",
    "Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.",
    "Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.  H.R. 1865, Further Consolidated Appropriations Act 2020.",
    "General education about policies impacting pharmaceutical development, approval and reimbursement.  \nS. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.  H.R. 1865, Further Consolidated Appropriations Act 2020.",
    "General education about policies impacting pharmaceutical development, approval and reimbursement.  \nS. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.  FY 2021 Appropriations.  Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201  Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748  CARES Act, Public Law No: 116-136.",
    "Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.  Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201  Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748  CARES Act, Public Law No: 116-136.",
    "Policies impacting Medicare Part D.  Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201  Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748  CARES Act, Public Law No: 116-136.",
    "Policies impacting Medicare Part D.  Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201  Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748  CARES Act, Public Law No: 116-136.  Financial Services and General Government Federal Trade Commission report."
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 33,
  "trajectory": "growing",
  "yearsActive": 8,
  "avgAnnualSpending": 187500,
  "peakYear": 2019,
  "lobbyistCount": 17,
  "firmCount": 1,
  "issueCount": 9,
  "industry": "healthcare"
}